血清NSE、CEA、CA125检测对肺癌患者^(125)I粒子植入术后短期疗效的预测价值

Predictive Value of Serum NSE,CEA,and CA125 Detection for Short-Term Efficacy after^(125)I Implantation in Patients with Lung Cancer

目的探讨血清神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)、糖类抗原125(CA125)检测对肺癌患者^(125)I粒子植入术后短期疗效的预测价值。方法选择2020年4月至2022年12月我院收治的86例肺癌患者,均行^(125)I粒子植入术,比较患者治疗前后血清NSE、CEA、CA125水平,评估疗效,对比不同疗效患者血清NSE、CEA、CA125水平,影响疗效的多因素采用Logistic回归分析。结果治疗后,患者血清NSE、CEA、CA125水平低于治疗前(P<0.05)。治疗有效组血清NSE、CEA、CA125水平低于治疗无效组(P<0.05)。NSE、CEA、CA125均为肺癌患者^(125)I粒子植入术治疗无效的独立危险因素(OR>1,P<0.05)。结论血清NSE、CEA、CA125水平是^(125)I粒子植入术治疗肺癌患者疗效的影响因素,可用于短期疗效预测。

Objective To explore the predictive value of serum neuron specific enolase(NSE),carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)for short-term efficacy after ^(125)I implantation in patients with lung cancer.Methods 86 patients with lung cancer admitted to our hospital from April 2024 to December 2022 were selected and given ^(125)I implantation.The serum NSE,CEA and CA125 levels before and after treatment were compared,and the efficacy was evaluated.The serum NSE,CEA and CA125 levels of patients with different efficacy were compared,and Logistic regression analysis was used to analyze the multiple factors that affected efficacy.Results After treatment,the serum NSE,CEA,and CA125 levels of patients were lower than those before treatment(P<0.05).The serum NSE,CEA,and CA125 levels of the effective group were lower than those of the ineffective group(P<0.05).NSE,CEA and CA125 were independent risk factors for ineffective ^(125)I implantation in patients with lung cancer(OR>1,P<0.05).Conclusions Serum NSE,CEA and CA125 levels are influencing factors for the efficacy of ^(125)I implantation in the treatment of patients with lung cancer,which can be used for short-term efficacy prediction.